FDA Approves The First Pill For Treating Postpartum Depression

Photo 44678982 © Golyak | Dreamstime.com

The US Food and Drug Administration (FDA) has given its approval to Zurzuvae (zuranolone), marking a significant milestone as the first oral medication designed to address postpartum depression (PPD).

Traditionally occurring after childbirth, PPD is a major depressive episode that can also manifest during the later stages of pregnancy. Previously, treatment options for the condition were limited to intravenous injections administered in specific healthcare facilities.

Distinguished by feelings of sadness, loss of interest in activities, and a reduced ability to experience pleasure, PPD shares common traits with other forms of depression. The condition can also present symptoms such as cognitive impairment, feelings of inadequacy, loss of energy, and even suicidal thoughts. Not to be confused with baby blues, which tend to be fleeting, PPD is more long-lasting.

Zurzuvae’s recommended daily dose is 50mg, to be taken once every evening with a fatty meal for 14 days. The medication’s approval was granted to Sage Therapeutics, Inc.

Clinical trials validating the effectiveness of Zurzuvae for treating PPD in adults involved two randomized, double-blind, placebo-controlled studies. 

Women with PPD who met the criteria for a major depressive episode, as per the Diagnostic and Statistical Manual of Mental Disorders, and whose symptoms began either during the third trimester of pregnancy or within four weeks of delivery, participated in the testing.

The results were promising, with patients receiving Zurzuvae showing significantly greater symptom improvement compared to those on the placebo. Even four weeks after the last dose of Zurzuvae, the positive effects of the treatment were maintained.

While Zurzuvae offers hope for those struggling with PPD, there are important considerations. The most common side effects include drowsiness, dizziness, diarrhea, fatigue, common cold symptoms, and urinary tract infection. Additionally, the medication may induce suicidal ideation and behavior, a side effect seen in many antidepressants, and even fetal harm. Women taking Zurzuvae are advised to use effective contraception during and for one week after the treatment.

Further, Zurzuvae’s label will address its potential impact on a person’s ability to drive and perform other hazardous activities due to its drowsy effect. Patients may find it challenging to assess their level of impairment, and, as a safety measure, they should steer clear from driving or operating heavy machinery for at least 12 hours after taking the medication.

Dr Tiffany R. Farchione, director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research, emphasized the seriousness of postpartum depression and its potential life-threatening consequences. She praised the approval of an oral medication as a beneficial option for many women dealing with extreme and potentially dangerous emotions.

“Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness—even, in severe cases, thoughts of harming themselves or their child,” notes Dr Farchione. “And, because postpartum depression can disrupt the maternal-infant bond, it can also have consequences for the child’s physical and emotional development.”

Dr Farchione adds: “Having access to an oral medication will be a beneficial option for many of these women coping with extreme, and sometimes life-threatening, feelings.”

As such treatments make their way to the market, they bring new hope to individuals facing the ever-present challenges of postpartum depression. With its efficacy demonstrated in clinical trials, this oral treatment offers an important alternative for those navigating the complexities of PPD—about one in seven women, according to the National Library of Medicine.

[via Engadget, CNN, Food and Drug Administration, cover photo 44678982 © Golyak | Dreamstime.com]